Adaptive Pharmacotherapy for Smoking Cessation

NCT02501265 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

188

Enrollment

OTHER

Sponsor class

Conditions

Nicotine Dependence

Interventions

BEHAVIORAL: Varenicline Standard Protocol
BEHAVIORAL: Nicotine Patch Standard Protocol
DRUG: Varenicline Adaptive Protocol
DRUG: Nicotine Adaptive Protocol

Sponsor

Duke University

Collaborators

[object Object]
[object Object]